Literature DB >> 31028138

Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope.

Laura Orellana1,2, Amy H Thorne3, Rafael Lema4, Johan Gustavsson5, Alison D Parisian3, Adam Hospital4, Tiago N Cordeiro6, Pau Bernadó7, Andrew M Scott8,9, Isabelle Brun-Heath4, Erik Lindahl10,2, Webster K Cavenee11, Frank B Furnari11, Modesto Orozco12,13.   

Abstract

Epidermal growth factor receptor (EGFR) signaling is initiated by a large ligand-favored conformational change of the extracellular domain (ECD) from a closed, self-inhibited tethered monomer, to an open untethered state, which exposes a loop required for strong dimerization and activation. In glioblastomas (GBMs), structurally heterogeneous missense and deletion mutations concentrate at the ECD for unclear reasons. We explore the conformational impact of GBM missense mutations, combining elastic network models (ENMs) with multiple molecular dynamics (MD) trajectories. Our simulations reveal that the main missense class, located at the I-II interface away from the self-inhibitory tether, can unexpectedly favor spontaneous untethering to a compact intermediate state, here validated by small-angle X-ray scattering (SAXS). Significantly, such intermediate is characterized by the rotation of a large ECD fragment (N-TR1), deleted in the most common GBM mutation, EGFRvIII, and that makes accessible a cryptic epitope characteristic of cancer cells. This observation suggested potential structural equivalence of missense and deletion ECD changes in GBMs. Corroborating this hypothesis, our FACS, in vitro, and in vivo data demonstrate that entirely different ECD variants all converge to remove N-TR1 steric hindrance from the 806-epitope, which we show is allosterically coupled to an intermediate kinase and hallmarks increased oncogenicity. Finally, the detected extraintracellular coupling allows for synergistic cotargeting of the intermediate with mAb806 and inhibitors, which is proved herein.

Entities:  

Keywords:  cancer; cryptoepitope; intermediate; mutational heterogeneity; structural convergence

Mesh:

Substances:

Year:  2019        PMID: 31028138      PMCID: PMC6525488          DOI: 10.1073/pnas.1821442116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.

Authors:  Terrance G Johns; Rodney B Luwor; Carmel Murone; Francesca Walker; Janet Weinstock; Angela A Vitali; Rushika M Perera; Achim A Jungbluth; Elisabeth Stockert; Lloyd J Old; Edouard C Nice; Antony W Burgess; Andrew M Scott
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

2.  Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.

Authors:  Terrance G Johns; Timothy E Adams; Jennifer R Cochran; Nathan E Hall; Peter A Hoyne; Mark J Olsen; Yong-Sung Kim; Julie Rothacker; Edouard C Nice; Francesca Walker; Gerd Ritter; Achim A Jungbluth; Lloyd J Old; Colin W Ward; Antony W Burgess; K Dane Wittrup; Andrew M Scott
Journal:  J Biol Chem       Date:  2004-04-09       Impact factor: 5.157

3.  CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor.

Authors:  Francesca Walker; Suzanne G Orchard; Robert N Jorissen; Nathan E Hall; Hui-Hua Zhang; Peter A Hoyne; Timothy E Adams; Terrance G Johns; Colin Ward; Thomas P J Garrett; Hong-Jian Zhu; Maureen Nerrie; Andrew M Scott; Edouard C Nice; Antony W Burgess
Journal:  J Biol Chem       Date:  2004-03-11       Impact factor: 5.157

Review 4.  Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors.

Authors:  Daniel J Leahy
Journal:  Adv Protein Chem       Date:  2004

5.  EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.

Authors:  Kathryn M Ferguson; Mitchell B Berger; Jeannine M Mendrola; Hyun Soo Cho; Daniel J Leahy; Mark A Lemmon
Journal:  Mol Cell       Date:  2003-02       Impact factor: 17.970

6.  The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor.

Authors:  Terrance G Johns; Ira Mellman; Glenn A Cartwright; Gerd Ritter; Lloyd J Old; Antony W Burgess; Andrew M Scott
Journal:  FASEB J       Date:  2005-03-17       Impact factor: 5.191

7.  Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.

Authors:  R B Luwor; T G Johns; C Murone; H J Huang; W K Cavenee; G Ritter; L J Old; A W Burgess; A M Scott
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

8.  Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display.

Authors:  Ginger Chao; Jennifer R Cochran; K Dane Wittrup
Journal:  J Mol Biol       Date:  2004-09-10       Impact factor: 5.469

9.  The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function.

Authors:  Dawn Mattoon; Peter Klein; Mark A Lemmon; Irit Lax; Joseph Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-19       Impact factor: 11.205

10.  A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.

Authors:  Achim A Jungbluth; Elisabeth Stockert; H J Su Huang; Vincent P Collins; Keren Coplan; Kristin Iversen; Denise Kolb; Terrance J Johns; Andrew M Scott; William J Gullick; Gerd Ritter; Leonard Cohen; Matthew J Scanlan; Webster K Cavenee; Lloyd J Old; Webster K Cavanee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-06       Impact factor: 11.205

View more
  16 in total

Review 1.  Towards gaining sight of multiscale events: utilizing network models and normal modes in hybrid methods.

Authors:  James M Krieger; Pemra Doruker; Ana Ligia Scott; David Perahia; Ivet Bahar
Journal:  Curr Opin Struct Biol       Date:  2020-07-01       Impact factor: 6.809

2.  Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.

Authors:  Yibo Yin; Jesse L Rodriguez; Nannan Li; Radhika Thokala; MacLean P Nasrallah; Li Hu; Logan Zhang; Jiasi Vicky Zhang; Meghan T Logun; Devneet Kainth; Leila Haddad; Yang Zhao; Tong Wu; Emily X Johns; Yu Long; Hongsheng Liang; Jiping Qi; Xiangtong Zhang; Zev A Binder; Zhiguo Lin; Donald M O'Rourke
Journal:  Mol Ther       Date:  2022-05-14       Impact factor: 12.910

3.  Exploring the Conformational Impact of Glycine Receptor TM1-2 Mutations Through Coarse-Grained Analysis and Atomistic Simulations.

Authors:  Anil Ranu Mhashal; Ozge Yoluk; Laura Orellana
Journal:  Front Mol Biosci       Date:  2022-06-28

4.  Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias.

Authors:  Chun Hu; Carlos A Leche; Anatoly Kiyatkin; Zhaolong Yu; Steven E Stayrook; Kathryn M Ferguson; Mark A Lemmon
Journal:  Nature       Date:  2022-02-09       Impact factor: 69.504

Review 5.  Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.

Authors:  Nan Li; Madeline R Spetz; Dan Li; Mitchell Ho
Journal:  Pharmacol Ther       Date:  2021-05-14       Impact factor: 13.400

6.  EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand.

Authors:  Youri Hoogstrate; Wies Vallentgoed; Johan M Kros; Iris de Heer; Maurice de Wit; Marica Eoli; Juan Manuel Sepulveda; Annemiek M E Walenkamp; Jean-Sebastien Frenel; Enrico Franceschi; Paul M Clement; Micheal Weller; Martin E van Royen; Peter Ansell; Jim Looman; Earle Bain; Marie Morfouace; Thierry Gorlia; Vassilis Golfinopoulos; Martin van den Bent; Pim J French
Journal:  Neurooncol Adv       Date:  2019-12-09

7.  Convergence of EGFR glioblastoma mutations: evolution and allostery rationalizing targeted therapy.

Authors:  Laura Orellana
Journal:  Mol Cell Oncol       Date:  2019-07-04

Review 8.  Large-Scale Conformational Changes and Protein Function: Breaking the in silico Barrier.

Authors:  Laura Orellana
Journal:  Front Mol Biosci       Date:  2019-11-05

9.  EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma.

Authors:  Ali C Ravanpay; Juliane Gust; Adam J Johnson; Lisa S Rolczynski; Michelle Cecchini; Cindy A Chang; Virginia J Hoglund; Rithun Mukherjee; Nicholas A Vitanza; Rimas J Orentas; Michael C Jensen
Journal:  Oncotarget       Date:  2019-12-17

10.  Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.

Authors:  Sindhu Nair; Hoa Q Trummell; Rajani Rajbhandari; Nanda K Thudi; Susan E Nozell; Jason M Warram; Christopher D Willey; Eddy S Yang; William J Placzek; James A Bonner; Markus Bredel
Journal:  PLoS One       Date:  2020-02-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.